222.1 Nocardiosis in living related donor kidney transplant recipients: A study from a low income country
Dr. Sana Jamil, Pakistan
222.2 Drop in peripheral blood Epstein-Barr virus nucleic acid loads after post-transplant lymphoproliferative disorders associates with better 5-year event-free survival: results from the multicenter PTLD-MSMS study
Vikas Dharnidharka, United States
222.4 Integrating single-cell RNA-seq and bulk RNA-seq reveals ischemic injury Promoting polyomavirus replication by DNA damage response
Prof. Gang Huang, People's Republic of China
222.5 Predictors of post-transplant CMV disease in kidney transplant recipients – A Collaborative Transplant Study (CTS) report
Dr. Elif Dogan Dar, Germany
222.6 Immune markers are predictive of CMV infection in seropositive lung transplant recipients
Dr. Bradley J Gardiner, Australia
222.7 Multinational, retrospective study assessing outcomes and healthcare resource utilization in solid organ transplant recipients with cytomegalovirus infection and refractory, resistance, or intolerance to anti-cytomegalovirus treatments: analysis of impact of viremia clearance on outcomes
Mrs. Kimberly H Davis, United States
222.8 Effect of recurrent CMV viremia on graft and patient survival in renal transplantation
Prof. Paul A Keown, Canada
222.9 Incidence of Antibiotic-Resistant Urinary Tract Infection after Kidney Transplant and Associated Antibiotic Use